Precion

Precion is a private U.S. diagnostics and precision medicine company focused on mass spectrometry-based biomarker assays for research, clinical diagnosis, and downstream commercial testing applications. The company develops targeted metabolite and small-molecule panels intended to generate actionable data for researchers, clinicians, and consumers. Publicly available descriptions emphasize its capabilities in assay development, validation, and technology transfer using liquid chromatography-tandem mass spectrometry. Precion has been identified as a U.S. development partner of BCAL Diagnostics for a blood-based breast cancer screening test, and its team has highlighted experience bridging biomarker discovery to commercialization. Available information suggests Precion operates as a specialized biomarker and assay-development company rather than a therapeutics developer.